Fig. 3.

In vivo CTL and B cell responses against exogenous antigen are inhibited by ABT-737 treatment. (A) B6 mice were treated daily for 14 consecutive d with either ABT-737 (75 mg/kg) (n = 8) or vehicle control (n = 8). On treatment day 6, mice were primed in vivo with irradiated, ovalbumin-coated splenocytes (OCS) and endogenous in vivo CTL responses measured in spleen and lymph node after 7 d. Means ± SE are shown. (B) B6 mice were immunized with NP-KLH in alum and then treated with ABT-737 (75 mg/kg) or vehicle control for 14 consecutive d starting either day 5 or day 40 after immunization. Spleens were analyzed for NP-specific GC or memory B cells on day 19 (Upper) or 54 (Lower). (C) Frequencies of total (NP₂₀) and high affinity (NP₂) NP-specific IgG₁ ASCs in BM on day 19 (Upper) or 54 (Lower) after immunization. Data are the average means ± SE of between six to eight mice for each group at each time point.